治疗溃疡性结肠炎和克罗恩病的新型抗炎药——mirikizumab  

New anti-inflammatory drugs for treating ulcerative colitis and Crohn’s disease:mirikizumab

作　　者：刘冰心 程卯生[1] 刘洋[1] LIU Bing-xin;CHENG Mao-sheng;LIU Yang(School of Pharmaceutical Engineering,Shenyang Pharmaceutical University,Key Laboratory of Target-based Drug Design and Research Discovery of Ministry of Education,Shenyang 110016,China)

机构地区：[1]沈阳药科大学制药工程学院、基于靶点的药物设计与研究教育部重点实验室,沈阳110016

出　　处：《临床药物治疗杂志》2022年第12期46-50,共5页Clinical Medication Journal

摘　　要：mirikizumab(研发代号:LY3074828)是一种能够与白细胞介素23(IL-23)的p19亚基特异性结合的人源化lgG4单克隆抗体,该药目前正在开发用于治疗多种免疫介导的疾病,包括溃疡性结肠炎(UC)、克罗恩病(CD)及斑块型银屑病等。mirikizumab通过与IL-23的p19亚基特异性结合,阻断IL-23/Th17的通路,降低IL-23的体内浓度,调控促炎因子Th17的表达,使炎症性肠病症状得到缓解,从而达到治疗目的。mirikizumab治疗UC和CD的Ⅱ期临床试验结果显示,无论是初期治疗还是维持治疗试验中,大部分患者均获得临床缓解和内镜改善,并且未发生安全性问题和耐药性。本文从mirikizumab的作用机制、临床试验等方面进行概述。Mirikizumab(research code:LY3074828)is a humanized lgG4 monoclonal antibody that binds to p19 subunit of interleukin 23(IL-23).This drug is currently developing to treat various immune-related diseases,including ulcerative colitis(UC),Crohn’s disease(CD)and plaques psoriasis.Mirikizumab blocks the pathway of IL-23/Th17 through the combination of p19 subunittism of IL-23,reducing the body concentration of IL-23,regulating the expression of inflammatory factor Th17,alleviating the symptoms of inflammatory bowel disease,so as to achieved the treatment purpose.PhaseⅡclinical trials of mirikizumab in the treatment of UC and CD showed that most patients experienced clinical remission and endoscopic improvement with no safety issues or drug resistance in both the initial treatment and maintenance treatment.This article summarizes the action mechanisms,clinical trials of mirikizumab.

关 键 词：mirikizumab 白细胞介素23 p19亚基 溃疡性结肠炎 克罗恩病 炎症性肠病 

分 类 号：R975[医药卫生—药品]